Home Featured Page 200

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

PharmaDrug Announces Initiation of Manufacturing of Cepharanthine (PD-001) For Clinical Programs...

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

Awakn Life Sciences Files Patent Application for a New Class of...

PT287 – Josh Hardman – Psychedelic Stocks, Data Privacy, and Drug...

Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical...

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety...

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in...

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its...

Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for...

Psychedelic Bulletin: DEA Moves to Schedule 5 Tryptamines; Eleusis Unveils SPAC;...

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.